TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06998407: A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in

Sponsor: Avenzo Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 380 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06998407 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06998407 Rescue Dossier →